Global Information
회사소개 | 문의 | 비교리스트

세계의 재조합 치료용 항체 및 단백질 시장 : 시장 규모, 시장 점유율, 동향, 예측

Recombinant Therapeutic Antibodies and Proteins Market - Size, Share, trends, and Forecast to 2026

리서치사 Coherent Market Insights
발행일 2018년 07월 상품 코드 678003
페이지 정보 영문
가격
US $ 4,500 ₩ 5,391,000 PPT Turned PDF (Single User License)
US $ 7,000 ₩ 8,387,000 PPT Turned PDF (Multi-user License)
US $ 10,000 ₩ 11,982,000 PPT Turned PDF (Enterprise User License)


세계의 재조합 치료용 항체 및 단백질 시장 : 시장 규모, 시장 점유율, 동향, 예측 Recombinant Therapeutic Antibodies and Proteins Market - Size, Share, trends, and Forecast to 2026
발행일 : 2018년 07월 페이지 정보 : 영문

재조합 치료용 항체 및 단백질은 중요시되고 있는 의약품 클래스의 하나로, 새로운 치료법을 필요로 하는 환자에게 유익합니다. 최근 승인된 재조합 단백질 치료제는 암, 자가면역질환, 유전자질환, 감염증 등의 폭넓은 질환을 치료하기 위해서 개발되었습니다. 단백질 공학 기술의 진보로 의약품 개발 기업 및 제약 기업에서는 단백질의 기능 특성을 조정하고, 의약품의 유효성을 확보하는 것이 가능해졌습니다. 단백질 기반 치료법은 매우 성공률이 높고, 그 유효성에 관해서는 유례 없는 성장 가능성이 있습니다.

세계의 재조합 치료용 항체 및 단백질(Recombinant Therapeutic Antibodies and Proteins) 시장에 대해 조사했으며, 시장 개요, 의약품 클래스·응용 영역·지역별 시장 규모 추정과 예측, 성장률, 성장 촉진요인 및 저해요인, 시장 기회, 기업 전략, 경쟁 상황, 주요 기업 개요 등의 정보를 전해드립니다.

목차

제1장 조사 목적과 가정

  • 조사 목적
  • 가정
  • 약어

제2장 시장 개요

  • 보고서 개요
    • 시장 정의와 범위
  • 주요 요약
    • 의약품 클래스별
    • 응용 영역별
    • 지역별
  • 시장 기회 분석

제3장 시장 역학, 규제, 동향 분석

  • 시장 역학
    • 성장 촉진요인
    • 성장 저해요인
    • 시장 기회
  • 시장 동향
  • 파이프라인 분석
  • 의약품 개발 과제
  • 새로운 시장 참여업체
  • 규제 시나리오
  • PEST 분석
  • Porter's Five Forces 분석

제4장 세계의 재조합 치료용 항체 및 단백질 시장 : 의약품 클래스별

  • 서론
  • 혈장 단백질
  • 성장인자
  • 융합 단백질
  • 단일클론항체
  • 호르몬
  • 효소
  • 응고인자
  • 기타

제5장 세계의 재조합 치료용 항체 및 단백질 시장 : 응용 영역별

  • 서론
  • 종양
  • 혈액질환
  • 면역질환
  • 내분비질환
  • 감염증
  • 순환기질환
  • 기타

제6장 세계의 재조합 치료용 항체 및 단백질 시장 : 지역별

  • 서론
  • 북미
  • 라틴아메리카
  • 유럽
  • 아시아태평양
  • 중동
  • 아프리카

제7장 경쟁 상황

  • 히트맵 분석
  • 기업 개요
    • Abbott
    • Amgen Inc.
    • Biogen Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche
    • Johnson and Johnson
    • Merck & Co.
    • Novo Nordisk
    • Pfizer Inc.
    • Sanofi S.A.
  • 애널리스트의 견해

제8장 부록

  • 참고 문헌
  • 조사 방법
  • Coherent Market Insights 소개
KSM 18.08.31

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Recombinant therapeutic protein drugs are an important class of medicines, which helps patients in need of novel therapies. Recently approved recombinant protein therapeutics have been developed to treat a wide variety of clinical indications, including cancers, inflammation/autoimmunity, genetic disorders, and exposure to infectious agents. The latest advancements in protein-engineering technologies have allowed drug manufacturers and developers to adjust desirable functional characteristics of proteins of interest maintaining product efficacy. Protein-based therapies are highly successful and experience unparalleled growth potential in terms of their efficacy.

Market Dynamics

Recombinant therapeutic proteins and antibodies have gained high traction in clinical applications. Due to development of antibody-based therapeutics, mammalian expression systems have experienced a major boost and microbial expression systems continue to be widely used in industries, which in turn will fuel growth of the market. However, variations in production methods of therapeutic antibodies can lead to differences in their structure, based on the selection of recombinant procedure. Most protein therapeutics available in the market are recombinant and majority of them are in clinical trials for therapy of immune disorders, cancers, infections, and other diseases. Various engineered proteins, including multi-specific fusion proteins, bi-specific monoclonal antibodies (mAbs) and mAbs conjugated small molecule drugs, and proteins with optimized pharmacokinetics are under development.

Key features of the study:

This report provides in-depth analysis of recombinant therapeutic antibodies and proteins market and provides market size (US$ Million) and cumulative annual growth rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players

It profiles leading players in the global recombinant therapeutic antibodies and proteins market based on the following parameters – company overview, financial performance, product portfolio, market presence, key developments, strategies, and future plans

Key companies covered as a part of this study include Abbott, Amgen Inc., Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Johnson and Johnson, Merck & Co., Novo Nordisk, Pfizer Inc., and Sanofi S.A.

Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics

The global recombinant therapeutic antibodies and proteins market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the recombinant therapeutic antibodies and proteins market

Detailed Segmentation:

  • Global Recombinant Therapeutic Antibodies and Proteins Market, By Drug Class:
  • Plasma Protein
  • Growth Factors
  • Fusion Proteins
  • Monoclonal Antibodies
  • Hormones
  • Enzyme
  • Coagulation Factors
  • Others
  • Global Recombinant Therapeutic Antibodies and Proteins Market, By Application:
  • Oncology
  • Hematology
  • Immunology
  • Endocrinology
  • Infectious Disease
  • Cardiovascular Diseases
  • Others
  • Global Recombinant Therapeutic Antibodies and Proteins Market, By Geography:
  • North America Recombinant Therapeutic Antibodies and Proteins Market
  • By Drug Class:
  • Plasma Protein
  • Growth Factors
  • Fusion Proteins
  • Monoclonal Antibodies
  • Hormones
  • Enzyme
  • Coagulation Factors
  • Others
  • By Application:
  • Oncology
  • Hematology
  • Immunology
  • Endocrinology
  • Infectious Disease
  • Cardiovascular Diseases
  • Others
  • By Country:
  • U.S.
  • Canada
  • Latin America Recombinant Therapeutic Antibodies and Proteins Market
  • By Drug Class:
  • Plasma Protein
  • Growth Factors
  • Fusion Proteins
  • Monoclonal Antibodies
  • Hormones
  • Enzyme
  • Coagulation Factors
  • Others
  • By Application:
  • Oncology
  • Hematology
  • Immunology
  • Endocrinology
  • Infectious Disease
  • Cardiovascular Diseases
  • Others
  • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe Recombinant Therapeutic Antibodies and Proteins Market
  • By Drug Class:
  • Plasma Protein
  • Growth Factors
  • Fusion Proteins
  • Monoclonal Antibodies
  • Hormones
  • Enzyme
  • Coagulation Factors
  • Others
  • By Application:
  • Oncology
  • Hematology
  • Immunology
  • Endocrinology
  • Infectious Disease
  • Cardiovascular Diseases
  • Others
  • By Country:
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific Recombinant Therapeutic Antibodies and Proteins Market
  • By Drug Class:
  • Plasma Protein
  • Growth Factors
  • Fusion Proteins
  • Monoclonal Antibodies
  • Hormones
  • Enzyme
  • Coagulation Factors
  • Others
  • By Application:
  • Oncology
  • Hematology
  • Immunology
  • Endocrinology
  • Infectious Disease
  • Cardiovascular Diseases
  • Others
  • By Country:
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East Recombinant Therapeutic Antibodies and Proteins Market
  • By Drug Class:
  • Plasma Protein
  • Growth Factors
  • Fusion Proteins
  • Monoclonal Antibodies
  • Hormones
  • Enzyme
  • Coagulation Factors
  • Others
  • By Application:
  • Oncology
  • Hematology
  • Immunology
  • Endocrinology
  • Infectious Disease
  • Cardiovascular Diseases
  • Others
  • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa Recombinant Therapeutic Antibodies and Proteins Market
  • By Drug Class:
  • Plasma Protein
  • Growth Factors
  • Fusion Proteins
  • Monoclonal Antibodies
  • Hormones
  • Enzyme
  • Coagulation Factors
  • Others
  • By Application:
  • Oncology
  • Hematology
  • Immunology
  • Endocrinology
  • Infectious Disease
  • Cardiovascular Diseases
  • Others
  • By Country:
  • North Africa
  • South Africa
  • Central Africa
  • Company Profiles
  • Abbott Laboratories*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Market Strategy
  • Amgen Inc.
  • Biogen Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche
  • Johnson and Johnson
  • Merck & Co.
  • Novo Nordisk
  • Pfizer, Inc.
  • Sanofi S.A.
  • “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Application
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Market Trends
  • Pipeline Analysis
  • Drug Development Challenges
  • New Market Entrants
  • Regulatory Scenario
  • PEST Analysis
  • Porter's Analysis

4. Global Recombinant Therapeutic Antibodies and Proteins Market, By Drug Class, 2016 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
  • Plasma Protein
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Growth Factors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Fusion Proteins
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Monoclonal Antibodies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Hormones
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Enzyme
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Coagulation Factors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

5. Global Recombinant Therapeutic Antibodies and Proteins Market, Application, 2016 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
  • Oncology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Hematology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Immunology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Endocrinology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Infectious Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Cardiovascular Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

6. Global Recombinant Therapeutic Antibodies and Proteins Market, By Region, 2016 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2026
    • Regional Trends
  • North America
    • Market Size and Forecast, By Drug Class, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Drug Class, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Drug Class, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Drug Class, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Drug Class, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • South Africa
    • Central Africa
    • North Africa

7. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Abbott*
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Market Strategy
    • Amgen Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Market Strategy
    • Biogen Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Market Strategy
    • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Market Strategy
    • F. Hoffmann-La Roche
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Market Strategy
    • Johnson and Johnson
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Market Strategy
    • Merck & Co.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Market Strategy
    • Novo Nordisk
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Market Strategy
    • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Market Strategy
    • Sanofi S.A.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Market Strategy
  • Analyst Views

8. Section

  • References
  • Research Methodology
  • About us and Sales Contact
Back to Top
전화 문의
F A Q